1. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study
- Author
-
Gabriella Melzi, Paolo Solla, Anna Rita Bentivoglio, Mariachiara Sensi, Giuliana Gualberti, Angelo Antonini, Filippo Tamma, Roberta Zangaglia, Nicola Modugno, Rocco Quatrale, Giuseppe Meco, Francesca Mancini, Graziano Gusmaroli, Leonardo Lopiano, Pietro Marano, and Roberto Eleopra
- Subjects
Male ,Parkinson's disease ,Routine patient care ,Antiparkinson Agents ,Cohort Studies ,Levodopa ,0302 clinical medicine ,Quality of life ,Clinical endpoint ,030212 general & internal medicine ,Prospective Studies ,Infusion Pumps ,Aged, 80 and over ,Gastrostomy ,Original Communication ,Levodopa/carbidopa ,Parkinson Disease ,Middle Aged ,Mental Status and Dementia Tests ,3. Good health ,Drug Combinations ,Settore MED/26 - NEUROLOGIA ,Jejunum ,Treatment Outcome ,Neurology ,Italy ,Carbidopa ,Cohort ,Female ,medicine.symptom ,medicine.drug ,medicine.medical_specialty ,Motor symptoms ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,carbidopa ,Adverse effect ,Aged ,Retrospective Studies ,Advanced Parkinson’s disease ,Intestinal infusion ,business.industry ,medicine.disease ,Advanced Parkinson's disease ,Dyskinesia ,Neurology (clinical) ,business ,Gels ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Introduction The GREENFIELD observational study assessed the effect of levodopa/carbidopa intestinal gel (LCIG) on motor and non-motor symptoms, and the related impact on patient quality of life and caregiver burden up to 8 years. Methods Final results of a large Italian cohort of patients who started LCIG in routine care between 2007 and 2014 are presented. Comparison between baseline (before LCIG) and follow-up visits on yearly basis (visit 2/3) is reported. Primary endpoint was Unified Parkinson’s Disease Rating Scale (UPDRS-IV) Item 39; secondary endpoints were UPDRS I and II, dyskinesia items, PD Quality of Life Questionnaire-39, Parkinson’s Disease Sleep Scale-2, Gait and Falls Questionnaire, Questionnaire on Impulsive Disorders, and Relative Stress Scale. Results Overall, 145 patients from 14 centers were assessed with a mean time since LCIG start of 2.8 ± 1.7 years at visit 2. The mean UPDRS-IV item 39 score showed significant reductions compared to baseline (mean score 2.0 ± 0.81) at visit 2 (mean score 0.9 ± 0.69; − 55%; p
- Published
- 2019